Lab Operations Manager
Addition Therapeutics
Lab Operations Manager
Addition Therapeutics
Develops non-viral RNA therapeutics for diseases
About the role
Addition Therapeutics is developing RNA-mediated genetic medicines. We are seeking a part-time contract Lab Operations Manager to help keep our research laboratories safe, organized, and have minimal disruption. Reporting to the Associate Director of Lab and Facility Operations, and collaborating with the Lab Administrator, this person will enable coordination of daily lab and facility activities and implement operational efficiency projects. The ideal candidate is proactive, organized, and comfortable balancing immediate operations needs with longer-term improvements.
The role combines hands-on laboratory support with vendor coordination and project execution. Priorities and project timelines will be agreed with the Associate Director to fit the contracted hours and laboratory needs.
Key responsibilities
Daily Laboratory Operations
Equipment & Vendor Management
Safety & Compliance
Lab Operations Projects
Required Qualifications
Preferred Qualifications
Work environment
This position requires regular on-site work in laboratory and equipment areas, use of required PPE, and hands-on support for inventory, shipments, and equipment coordination. The weekly schedule will be agreed in advance to support laboratory coverage and scheduled vendor activities.
Compensation
This is a contract position with an estimated hourly rate of $65-$70. Exact compensation may vary based on skills and experience.
We are an Equal Opportunity employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status.
Develops non-viral RNA therapeutics for diseases
Addition Therapeutics develops genomic medicines using a non-viral, all-RNA approach delivered by LNPs (lipid nanoparticles) through its PRINT platform. Its product strategy focuses on creating one-time, durable therapies for chronic and rare diseases, instead of traditional multi-dose treatments. The platform enables RNA therapies to be packaged and delivered without viral vectors, aiming for safer delivery and longer-lasting effects. Compared with others, its PRINT-based, non-viral method aims to offer stronger safety profiles and durable responses, along with a pipeline of therapeutics that can be clinically meaningful for patients with difficult-to-treat conditions. The company’s goal is to realize the transformative potential of genomic medicine by delivering safe, durable, one-time treatments that address unmet medical needs in chronic and rare diseases.
Explore more opportunities at Addition Therapeutics